You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

CLINICAL TRIALS PROFILE FOR OPDUALAG


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OPDUALAG

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05704933 ↗ Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Recruiting Bristol-Myers Squibb Early Phase 1 2023-01-19 The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
NCT05704933 ↗ Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases Recruiting H. Lee Moffitt Cancer Center and Research Institute Early Phase 1 2023-01-19 The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OPDUALAG

Condition Name

Condition Name for OPDUALAG
Intervention Trials
Metastasis to Brain 1
Metastatic Melanoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OPDUALAG
Intervention Trials
Brain Neoplasms 1
Neoplasm Metastasis 1
Melanoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OPDUALAG

Trials by Country

Trials by Country for OPDUALAG
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OPDUALAG
Location Trials
Texas 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OPDUALAG

Clinical Trial Phase

Clinical Trial Phase for OPDUALAG
Clinical Trial Phase Trials
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OPDUALAG
Clinical Trial Phase Trials
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OPDUALAG

Sponsor Name

Sponsor Name for OPDUALAG
Sponsor Trials
Bristol-Myers Squibb 1
H. Lee Moffitt Cancer Center and Research Institute 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OPDUALAG
Sponsor Trials
Industry 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.